Skip to content
Parakho

Indoco Remedies Ltd

NSE INDOCOBSE 532612

Q1 FY27, unaudited

Revenue
₹467.50 Cr
Profit after tax
₹65.44 Cr

As filed with the exchange, consolidated basis.

Statement of profit and loss

Figures in ₹ crore, reproduced from the results data files the company filed with NSE under Regulation 33 of the SEBI (LODR) Regulations. Nothing is restated, adjusted or estimated.

Statement of profit and loss, consolidated basis
₹ croreQ1 FY27vs a year agoFY26
Revenue from operations467.50+6.76%1,845.32
Other income2.18+33.74%3.33
Total income469.68+6.86%1,848.65
Employee benefit expense101.41−5.24%425.69
Finance costs28.29+8.31%122.25
Depreciation & amortisation34.53+16.26%126.45
Total expenses489.30+2.76%1,952.22
Profit before tax77.72+312.00%-106.51
Tax expense12.28+4,061.29%-7.81
Profit after tax65.44+280.03%-98.70
Total comprehensive income66.12+281.10%-86.08
Earnings per share
Earnings per share, basic₹7.09₹-10.70
Earnings per share, diluted₹7.09₹-10.69

Q1 FY27 — unaudited, from the company’s filing with NSE. Source

Q1 FY26, the year-ago base — unaudited, from the company’s filing with NSE. Source

FY26 — from the company’s filing with NSE. Source

Q1 FY27 results for every company Parakho holds

Earnings call

Q1 FY27

Indoco Remedies reported standalone revenue growth of 5.8% year-on-year to Rs 4,081 million in Q1 FY27, with consolidated revenue up 8.2% to Rs 4,662 million. Standalone EBITDA margin expanded to 10.3% from 3.8% a year earlier, aided by cost efficiency measures including a reduction in headcount and fewer manufacturing batches. Management discussed regulatory approvals across its Baddi and Goa facilities, a pending USFDA audit for its sterile plant, and flat performance in European and emerging markets which it attributed to timing and one-off factors.

Generated by AI from the filed transcript; every statement on the full page carries its verbatim quote.

Read the full summary

Earlier calls: Q4 FY26 · All quarters

Filings

12 shown · 49 published by the exchange

BSE corporate announcements, classified by Parakho. The exchange’s own category is kept alongside our classification so a reclassification never rewrites history.

Industry

Healthcare › Pharmaceuticals

Classification as published by BSE.

Companies also in Pharmaceuticals, in alphabetical order

All 196 companies in Pharmaceuticals

Page generated from filings held to 07 Oct 2026.